Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anifrolumab Long-term Extension in SLE
NCT02794285Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2016
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 24
01
Overview
A Phase 3 trial of anifrolumab in systemic lupus erythematosus (SLE), sponsored by AstraZeneca. Started Jun 2016; status: completed.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02794285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02794285.